Shekhar Swaroop

Dr. Shekhar Swaroop

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2023 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
UAUmang Arora
Umang Arora
RGRitik M. Goyal
Ritik M. Goyal
KTKevin K. J. Teh
Kevin K. J. Teh
YPYiying Pei
Yiying Pei
GGGeorge Boon Bee Goh
George Boon Bee Goh
.S. Shalimar
. Shalimar

21 November 2022 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
SSShekhar Swaroop
Shekhar Swaroop
UAUmang Arora
Umang Arora
SBSagnik Biswas
Sagnik Biswas
MVManas Vaishnav
Manas Vaishnav
PPPiyush Pathak
Piyush Pathak
.S. Shalimar
. Shalimar

16 July 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MVManas Vaishnav
Manas Vaishnav
SBSagnik Biswas
Sagnik Biswas
AAAbhinav Anand
Abhinav Anand
PPPiyush Pathak
Piyush Pathak
SSShekhar Swaroop
Shekhar Swaroop
.S. Shalimar
. Shalimar
Background: The role of hepatic venous pressure gradient (HVPG) in predicting further decompensation in cirrhosis patients with acute variceal bleeding (AVB) is not known. We aimed to evaluate the role of HVPG in predicting further decompensation in cirrhosis patients with AVB Methods: In this prospective study, 145 patients with cirrhosis with esophageal or gastric AVB were included. HVPG was measured on the day of the AVB. Decompensating events occurring after 42-days of AVB were considered further decompensation. Results: The median age of the study cohort was 44 years; 88.3% males. The predominant etiology of cirrhosis was alcohol (46.2%). Overall, 40 (27.6%) patients developed further decompensation during median follow-up of 296 days following AVB. Gastro intestinal bleeding n = 27 (18.6%) and new-onset/worsening ascites n = 20 (13.8%) were the most common decompensating events. According to the multivariate model, HVPG was an independent predictor of any further decompensation in esophageal AVB patients but not in gastric variceal bleeding patients. HVPG cut-off of ≥16 mmHg predicted further decompensation in the esophageal AVB. However, HVPG was not an independent predictor of mortality. Conclusion: HVPG measured during an episode of acute variceal hemorrhage from esophageal varices predicts further decompensating events in cirrhosis patients.

27 July 2025 in Digestive and Liver Disease
Verified
Journal Article
Closed access
SSShekhar Swaroop
Shekhar Swaroop
AJAsisha M Janeela
Asisha M Janeela
AVARUN VALSAN
ARUN VALSAN
SBSagnik Biswas
Sagnik Biswas
VAVijay Alexander
Vijay Alexander
.S. Shalimar
. Shalimar

6 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSShekhar Swaroop
Shekhar Swaroop
SBSagnik Biswas
Sagnik Biswas
SMShubham Mehta
Shubham Mehta
AAArnav Aggarwal
Arnav Aggarwal
UAUmang Arora
Umang Arora
.S. Shalimar
. Shalimar
Background/Objectives: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy. Barcelona Clinic Liver Cancer (BCLC) guidelines recommend antiangiogenic agents with immune checkpoint inhibitors as first-line therapy for advanced HCC. We present our experience of treating HCC patients with Atezolizumab–Bevacizumab, their response rates, adverse events, survival, and response and survival predictors. Methods: This retrospective analysis included HCC patients diagnosed at All India Institute of Medical Sciences, New Delhi, India between July 2021 and April 2024 and receiving at least one dose of Atezolizumab–Bevacizumab. The primary outcome was overall response rate (ORR), comprising complete response (CR) and partial response (PR), as per mRECIST criteria. Secondary outcomes were overall survival (OS), progression-free survival (PFS), and predictors of response and survival. Results: Sixty-three patients were analyzed {mean age: 56.0 + 12.7 years; 82.5% males}. Forty-three (68.2%) patients had BCLC stage C HCC. Thirty-five (55.5%) patients belonged to Child–Pugh class A and 28 (44.5%) belonged to Child–Pugh class B. At 1 year, OS was 39% and PFS was 27%. Among 43 patients with data for radiological response, ORR was 48.8% (CR—9.3% and PR—39.5%) and DCR was 62.7% with stable disease (SD) in 13.9% of patients. PD occurred in 37.2% of patients. AFP response predicted radiological response, while Child–Pugh class and BCLC stage predicted survival. Adverse events were reported in 49.2% of patients. Conclusions: Our study shows slightly lower survival than previous studies with Child–Pugh class being the most important determinant of survival. AFP response predicts radiological response and not survival.

8 April 2025 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
SSShekhar Swaroop
Shekhar Swaroop
SBSagnik Biswas
Sagnik Biswas
SMShubham Mehta
Shubham Mehta
AAArnav Aggarwal
Arnav Aggarwal
UAUmang Arora
Umang Arora
BNBaibaswata Nayak
Baibaswata Nayak